



**Founded**  
May 2000

**Location**  
Heidelberg, Germany

**Number of employees**  
23

**Focus**  
Discovery and development of new innovative antibody therapies focused on unmet medical needs in large expanding cancer indications

**Technologies**  
Antibody libraries –

- naïve library of human antibodies
- fully synthetic library of human antibodies
- combined naïve and synthetic library of human antibodies

TandAbs - Proprietary tetravalent antibody formats

**Products**

- CD19 x CD3 for Non-Hodgkin's Lymphoma, esp. B-CLL
- CD19 x CD16A for Non-Hodgkin's Lymphoma, esp. B-CLL
- CD30 x CD16A for Hodgkin's Disease
- Anti-GPIIb/IIIa for Thrombosis
- Anti-CD3 for Auto immune diseases
- Anti-CD16A for Auto immune diseases

Additional programmes developing lead candidates for Leukaemia, Autoimmune diseases, Myeloma, solid tumors, metastasis, allergy, asthma and Non-Hodgkin's Lymphoma.

**Contact details**  
Affimed Therapeutics AG  
Technologiepark  
Im Neuenheimer Feld 582  
Heidelberg  
D-69120  
Germany  
t: 49- 6221-65307-0  
f: 49- 6221-65307-77  
info@affimed.com  
www.affimed.com

**Last update**  
April 2007

**OUR MISSION:** Our mission is to become a leader in the discovery and development of next generation antibodies for the treatment of cancer and other diseases with unmet medical need.

### Company Profile

Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. The Company's powerful research engine, based around three distinct antibody libraries and proprietary antibody formats, is driving the development of a strong, broad portfolio of antibodies that target cancer and other diseases. The unique properties of these libraries allow Affimed to identify antibodies against even the most difficult of targets. Affimed's proprietary antibody formats include 'TandAbs™', unique tetravalent antibodies that are particularly well suited to targeting tumor cells. Affimed's two most advanced therapeutic programs, in late preclinical development, comprise TandAbs™ leads in Non-Hodgkin's Lymphoma and Hodgkin's Disease. Affimed is based in Heidelberg, Germany.

### Antibody Libraries

To be the leader in antibody research, Affimed has assembled one of the industry's most powerful research engines as a formidable resource for in-house antibody discovery. The core of this technology comprises three distinct antibody libraries that can be screened using phage display to identify antibodies to address even the most difficult of targets. Affimed's three libraries are:

- a naïve library derived from the immune system's antibody gene repertoire,
- a fully synthetic library of human antibodies, and
- a semi-synthetic library of human antibodies combining aspects of both naïve and synthetic antibody libraries.

The use of all three antibody libraries ensures a high diversity of potential leads and by extension, a higher probability of isolating very specific human antibodies against any target. The power of this library-based research engine significantly increases the likelihood of isolating commercially relevant antibodies. This means that Affimed is unique in being able to tackle targets that would traditionally have remained extremely difficult for the established methods commonly used by antibody companies. The quality of Affimed's libraries and its screening expertise have been validated over a number of years through programs for partners and for in house discovery, in particular the isolation of antibodies targeting complex cell surface molecules that were thought to be too difficult using traditional methods.

### Novel antibody formats – TandAb™ technology

Traditionally, fully human IgG antibodies (while ideal for some targets), lack the versatility to address some others for a variety of reasons including size. Affimed has therefore developed an array of proprietary antibody formats including IgG antibodies, Fabs, Diabodies, Flexibodies and TandAbs. TandAbs in particular have proved to be particularly well suited in targeting tumor cells. These unique tetravalent antibodies have been combined with Affimed's proprietary technology for the recruitment of cytotoxic immune cells, to generate a number of highly potent reagents for top cancer indications. Affimed's TandAb for recruiting and activating T cells to treat Non-Hodgkin-Lymphoma has demonstrated significant potency in *in vivo* and *in vitro* preclinical studies.



### Funds raised

of €35.3 million in two rounds of venture capital fundraising and from grants.

### Key Shareholders

- SHS
- Tbg
- firstVentury
- KfW
- BioMedInvest AG
- Orbimed
- Life Science Partners

### Management

**Dr. Rolf H. Günther**,  
Chief Executive Officer

**Prof. Dr. Melvyn Little**, Chief  
Scientific Officer, deputy CEO

**Dr. Florian Fischer**,  
Chief Financial Officer

**Dr. Miroslav Ravic**,  
Chief Medical Officer

**Gavin D. Clark**,  
VP Business Development

### Board of Directors

**Dr. Gerhard Ries**, Chairman,  
General Partner at BioMedInvest

**Dr. Michael Sheffery**, General  
Partner at OrbiMed

**Dr. Frank Mühlenbeck**, General  
Partner at firstVentury Equity  
GmbH

### Founder

Professor Melvyn Little, German  
Cancer Research Center in  
Heidelberg

### Contact details

Affimed Therapeutics AG  
Technologiepark  
Im Neuenheimer Feld 582  
Heidelberg  
D-69120  
Germany  
t: 49- 6221-65307-0  
f: 49- 6221-65307-77  
info@affimed.com  
www.affimed.com

### Last updated

April 2007

### Products

Affimed's product pipeline includes candidates with a high market potential in the indications of oncology, thrombosis and auto-immune diseases. Currently, several products are in an advanced preclinical stage, while additional, new antibody leads have been isolated for major cancer indications. Affimed's lead programs are TandAbs for the treatment of Non-Hodgkin's Lymphoma (AFM11 and AFM12) and Hodgkin's Disease (AFM13). These lead programs address validated targets for these diseases that are particularly amenable to the TandAb format. Additional preclinical programs address Thrombosis (AFM14) and Autoimmune Disease (AFM15).



### Business Development

Affimed intends to take its two lead products up to Clinical proof of concept and would be interested in hearing from potential licensing partners in order to realise the commercial potential of other programmes.

### Investors

Affimed has raised a total of €35.3 million in two rounds of venture capital fundraising and from grants. The most recent fundraising completed in March 2007 and raised a total of €25 million from a consortium of investors. As well as the founders, there are seven current shareholders: SHS (Gesellschaft für Beteiligungsmanagement mbH), tbg (Technologiebeteiligungsgesellschaft), firstVentury, KfW (Kreditanstalt für Wiederaufbau), BioMedInvest AG, Orbimed and Life Science Partners.